GLPG Stock Analysis: Buy, Sell, or Hold?
GLPG - Galapagos NV
$27.73
-1.08 (-3.75%)
âŧ
5d:
-0.36%
30d:
-4.02%
90d:
-16.93%
WAIT
LOW Confidence
Analysis Updated: May 7, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When GLPG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GLPG is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GLPG is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GLPG is currently trading at $27.73, which is considered fair based on recent price action. From a valuation perspective, the stock is trading at a discount (Forward PE: -20.3) compared to its historical average (163.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GLPG is in a strong downtrend. The price is currently testing key support at $27.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GLPG is in a strong downtrend. The price is currently testing key support at $27.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
46/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
62.9%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BEARISH: Downward momentum (-3.7%)
- NEUTRAL: Near Wall St target ($28.56)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$27.15
Resistance Level
$28.97
Current Trend
Strong Downtrend
Technical data as of
May 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.32
Wall Street Target
$28.56
(+3.0%)
Revenue Growth (YoY)
1093.2%
Earnings Growth (YoY)
3036.0%
Profit Margin
28.8%
PE vs Historical
-20.3 vs 163.5
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 7:29 PM ET
Data refreshes hourly during market hours. Next update: 8:29 PM
Data refreshes hourly during market hours. Next update: 8:29 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLPG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |
